Summary
The Far Eastern and Caucasian populations are strikingly different with respect to the debrisoquine/sparteine hydroxylation polymorphism. The number of poor metabolizers, as defined for Caucasians, is very low among Chinese and Japanese. We investigated the molecular basis for this difference by analysis of the CYP2D6 gene in 115 Chinese subjects, combined with phenotypic classification of codeine and debrisoquine metabolism.
A correlation between the rates of metabolism of these two drugs and genotype, as analyzed by RFLP using XbaI, was observed among the Chinese. A high frequency (37%) of alleles indicative of gene insertions (reflected by Xba I 44kb fragments) was recorded in the Chinese, but was not associated with the poor metabolizer phenotype, as it is in Caucasians. PCR amplification of part of the CYP2D6 gene with mutation specific primers for CYP2D6A (29A) and CYP2D6B (29B) allelic variants revealed that the XbaI 44kb fragment in Chinese apparently contains a functional CYP2D6 gene, in contrast to the situation among Caucasians.
The results provide a molecular explanation of the interethnic difference in the metabolism of drugs affected by the debrisoquine hydroxylation polymorphism.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet II: 584–586
Tucker GT, Silas JH, Iyun AO, Lennard MS, Smith AJ (1977) Polymorphic hydroxylation of debrisoquine. Lancet II: 718
Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16: 183–187
Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspects. Pharmacol Ther 46: 377–394
Brøsen K, Gram LF (1989) Clinical significance of sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36: 537–547
Zanger UM, Vilbois F, Hardwick J, Meyer UA (1988) Absence of hepatic cytochrome P450buf1 causes genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447–5454
Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 265: 17209–17214
Hanioka N, Kimura S, Meyer UA, Gonzalez FJ (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: A G1934→A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Gen 47: 994–1001
Gaedigk A, Blum M, Meyer UA, Eichelbaum M (1990) Sparteine/debrisoquine polymorphism of drug oxidation: the 11.5 kb allele is the result of a deletion of the IID6 gene on chromosome 22. Naunyn-Schmied Arch Pharmacol 341 [Suppl]: abstract 435
Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105
Steiner E, Bertilsson L, Säwe J, Bertling I, Sjöqvist F (1988) Polymorphic debrisoquine hydroxylation in 757 Swedish subjects. Clin Pharmacol Ther 44: 431–435
Lou YC, Liu Y, Bertilsson L, Sjöqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet II: 852–853
Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408
Ishizaki T, Eichelbaum M, Horai Y, Hashimoto K, Chiba K, Dengler HJ (1987) Evidence for polymorphic oxidation of sparteine in Japanese subjects. Br J Clin Pharmacol 23: 482–485
Horai Y, Nakeno M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, Liao C-L, Zhang L-M (1989) Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 46: 198–207
Skoda RC, Gonzalez FJ, Demierre A, Meyer UA (1988) Two mutant alleles of the human cytochrome P450db1 gene (P450IID1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 85: 5240–5243
Heim M, Meyer UA (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529–532
Yue QY, Bertilsson L, Dahl-Puustinen M-L, Säwe J, Sjöqvist F, Johansson I, Ingelman-Sundberg M (1989) Disassociation between debrisoquine hydroxylation phenotype and genotype among Chinese. Lancet II: 870
Yue QY, Bertilsson L, Dahl-Puustinen M-L, Säwe J, Sjöqvist F, Johansson I, Ingelman-Sundberg M (1989) Debrisoquine phenotype and genotype in Chinese. Lancet II: 1534
Yue QY, Svensson JO, Alm C, Sjöqvist F, Säwe J (1989) Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. Br J Clin Pharmacol 28: 629–637
Yue QY, Svensson JO, Alm C, Sjöqvist F, Säwe J (1989) Codeine demethylation co-segregates with polymorphic debrisoquine hydroxylation. Br J Clin Pharmacol 28: 639–645
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Johansson, I., Yue, Q.Y., Dahl, ML. et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 40, 553–556 (1991). https://doi.org/10.1007/BF00279968
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00279968